Wegovy 1.7mg vs Mounjaro: Which Suits Your Needs?
Wegovy 1.7mg vs Mounjaro: Mechanism Comparison
Wegovy 1.7mg contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro (tirzepatide) takes a dual approach, targeting both GLP-1 and GIP receptors for appetite regulation. At the Wegovy 1.7mg stage, you're experiencing the penultimate dose strength before reaching 2.4mg maintenance, while Mounjaro users typically start at 2.5mg and can escalate to 15mg. Both prescription-only medicines work alongside a reduced-calorie diet and increased physical activity.
The choice between continuing Wegovy 1.7mg escalation versus switching to Mounjaro depends on your individual response and clinical needs. Wegovy's established dose progression means predictable escalation to maintenance, while Mounjaro offers different dosing flexibility. Your prescriber can assess which mechanism suits your weight management goals, considering factors like side effect tolerance and treatment response at the Wegovy 1.7mg level.
Wegovy 1.7mg vs Mounjaro: Pricing and Value Analysis
Wegovy 1.7mg costs £139.99 as a single pen, representing excellent value at this crucial escalation stage before maintenance. The Elevate Duo bundle combines Wegovy 1.7mg with 2.4mg maintenance for £369.99, providing a seamless transition path. Mounjaro pricing varies by strength, with our transparent pricing structure ensuring you understand costs upfront. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 for continued savings.
When comparing Wegovy 1.7mg costs against equivalent Mounjaro stages, consider the total treatment journey rather than individual pen prices. The Consistency 1.7mg bundle (two pens) costs £309.99 for patients who may need extended time at this dose level. Both medications require ongoing prescription-only medicine supply from our GPhC-registered pharmacy (#9012878), with next-day cold-chain delivery ensuring medication integrity regardless of your choice.
Clinical Evidence: Wegovy 1.7mg Stage vs Mounjaro Trials
The Wegovy 1.7mg dose represents a critical escalation point in the STEP trial protocols, where patients experienced progressive appetite reduction before reaching maintenance dosing. In clinical trials, patients taking Wegovy 1.7mg alongside diet and exercise demonstrated continued weight management benefits as cited in Wilding et al., NEJM, 2021. This dose bridges the gap between initial tolerance building and full therapeutic effect.
Mounjaro's SURMOUNT trials followed different dosing schedules, making direct comparison challenging but highlighting both medications' effectiveness. The Wegovy 1.7mg stage typically occurs at weeks 13-16, when patients often report significant appetite changes and eating pattern modifications. Individual responses vary, and your prescriber can assess which medication pathway aligns with your clinical presentation.
How Wegovy 1.7mg Works in Your Body
Wegovy 1.7mg delivers semaglutide that binds to GLP-1 receptors in your brain's appetite centres, mimicking the natural hormone released when you eat. This mechanism promotes feeling full sooner during meals and reduces food cravings between eating occasions. The 1.7mg strength provides substantial receptor activation while maintaining tolerability before the final escalation to 2.4mg maintenance. Unlike faster-acting medications, Wegovy 1.7mg works gradually to recalibrate your hunger and satiety signals. The once-weekly injection via FlexTouch pen ensures consistent medication levels, supporting sustainable appetite management throughout your treatment journey.
Ordering Wegovy 1.7mg vs Mounjaro Process
Both Wegovy 1.7mg and Mounjaro require identical ordering processes through our streamlined clinical assessment system. Complete our 3-minute online questionnaire detailing your weight management history, current medications, and treatment goals. Our prescribers review applications within 3 working days (express 24-hour service available), ensuring appropriate medication selection whether continuing Wegovy 1.7mg escalation or considering Mounjaro. Once approved, both medications ship via next-day cold-chain delivery to maintain temperature integrity. Our clinical team provides ongoing support for either treatment pathway, helping optimize your chosen medication for best results.
Storage and Practical Considerations: Wegovy 1.7mg vs Mounjaro
Wegovy 1.7mg offers superior travel convenience with 6 weeks room temperature storage below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. Both medications require 2-8°C refrigeration before first use, but Wegovy's extended room temperature stability suits active lifestyles better. The FlexTouch pen design delivers precise 1.7mg doses with audible click confirmation, while Mounjaro uses similar pen technology at different dose increments. Dose escalation cannot be skipped with Wegovy 1.7mg, ensuring safety protocols, whereas Mounjaro follows its own structured progression. Both require weekly injection scheduling, typically on the same day each week for consistency.
Wegovy 1.7mg vs Mounjaro: Advanced Treatment Considerations
At the Wegovy 1.7mg stage, patients often experience peak appetite suppression before stabilizing at 2.4mg maintenance, making this a crucial decision point for treatment continuation. Some patients may consider switching to Mounjaro if experiencing specific side effects or seeking alternative mechanisms. The transition between medications requires careful prescriber supervision and cannot be done independently.
Wegovy 1.7mg represents 13-16 weeks of established treatment, meaning your body has adapted to GLP-1 receptor activation through previous doses. Mounjaro's dual receptor approach may offer different benefits, but switching means starting a new dose escalation schedule. Our clinical team, working under GPhC registration #9012878, provides personalized guidance for these complex treatment decisions based on your individual response patterns.
Making Your Choice: Wegovy 1.7mg Continuation or Mounjaro Switch
EverydayMeds stocks both medications because we recognize that weight management requires personalized approaches rather than one-size-fits-all solutions. Whether continuing your Wegovy 1.7mg escalation toward 2.4mg maintenance or exploring Mounjaro's alternative pathway, our prescription-only medicine supply ensures consistent access to your chosen treatment. Use code DOSE25 if you're a returning customer, or FIRST40 for new patients, both applied at checkout for transparent pricing. Visit https://everydaymeds.co.uk/collections/weight-loss to compare both options with detailed prescriber information supporting your decision. Both medications are available from our UK pharmacy with next-day delivery, clinical support, and ongoing monitoring throughout your weight management journey. Your prescriber can help determine which medication pathway aligns with your individual goals and treatment response patterns.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
